UPDATE : Monday, September 7, 2020
상단여백
[News Focus] Valsartan chaos reveals Korean drugmakers’ weakness
The pharmaceutical industry is having time for self-reflection, admitting t...
by So Jae-hyeon  |  2018-08-13 14:21
라인
Janssen Korea to observe 120 for post-marketing survey of ulcerative colitis treatment
The number of cases for additional indications of ulcerative colitis after ...
by Lee Hye-seon  |  2018-08-10 18:25
라인
Pfizer Vitals suffers double-whammy from poor performance, valsartan recall
Pfizer Vitals, which claimed to stand for quality generics, has suffered a ...
by So Jae-hyun  |  2018-08-10 17:56
라인
Cannabinoid group uses blockchain to conduct clinical trials on CBD
Kwon Yong-hyun (second from left), president of the Korean Cannabinoid Asso...
by Lee Han-soo  |  2018-08-10 14:53
라인
Daewoong, Chong Kun Dang compete to develop dementia treatments
The rivalry between Daewoong Pharmaceutical and Chong Kun Dang is getting i...
by So Jae-hyun  |  2018-08-09 15:55
라인
JW to launch drug combining Livaro, Ezetimibe
JW Pharmaceuticals has begun to develop a drug which combines two dyslipide...
by Lee Hye-seon  |  2018-08-09 11:59
라인
Competition heats up among Korean Botox makers to develop ‘kDa’
As the global expansion of domestic botulinum toxin (BTX) products is becom...
by So Jae-hyeon  |  2018-08-08 16:53
라인
GSK publishes SWORD data on 2-drug HIV regimen
ViiV Healthcare, the HIV specialty firm of GlaxoSmithKline, presented 100-w...
by Marian Chu  |  2018-08-08 14:42
라인
Takeda gets approval for antihypertension drug Edarbyclor
Takeda Pharmaceutical Korea said Tuesday it got approval for its antihypert...
by Marian Chu  |  2018-08-07 17:24
라인
Bukwang registers patients for P2 clinical trial of diabetes treatment
Bukwang Pharmaceutical said Tuesday that it has finished enrolling patients...
by Lee Han-soo  |  2018-08-07 17:24
라인
Over 36.8 billion won worth of banned valsartan-based drugs sold last year
More than 36.9 billion won worth of banned antihypertensive drugs were pres...
by So Jae-hyeon  |  2018-08-07 15:40
라인
59 Korea-made high blood pressure medications called back over cancer fears
Locally produced antihypertensive medication containing the active ingredie...
by Marian Chu  |  2018-08-06 17:50
라인
Chong Kun Dang gets license for generic immunosuppressant
Chong Kun Dang said it has obtained approval for Raparobell, a generic copy...
by So Jae-hyeon  |  2018-08-03 15:38
라인
GC Labcell, AbClon to develop CAR-NK cell treatment
GC Labcell CEO Park Dae-woo (left) and AbClon CEO Lee Jong-seo signed a coo...
by Lee Han-soo  |  2018-08-03 14:40
라인
Korean drugmakers rush to establish US subsidiaries
Local pharmaceutical companies are rushing to establish subsidiaries in the...
by So Jae-hyeon  |  2018-08-03 14:40
라인
Genexine, National OncoVenture to develop cervical cancer immunotherapy vaccine
Genexine said Thursday that it has signed an agreement with National OncoVe...
by Lee Han-soo  |  2018-08-02 17:33
라인
Expert advises against ‘doctor-shopping’ for uveitis treatment
A Korean expert noted the difficulties of treating uveitis in Korea, saying...
by Marian Chu  |  2018-08-02 15:37
라인
Pharmacists, convenience store owners in dispute over OTC drugs
The group of Korean pharmacists and that of convenience store owners are sl...
by So Jae-hyeon  |  2018-08-02 15:32
라인
Daewoong Bio’s dementia drug hits 3-digit sales growth
Industry watchers are paying attention to whether rising sales of generic d...
by So Jae-hyeon  |  2018-08-01 15:50
라인
GC increases in sales but loses profit in Q2
GC and its affiliates managed to increase its sales in the second quarter o...
by Lee Han-soo  |  2018-08-01 15:14
여백
여백
여백
Back to Top